143 related articles for article (PubMed ID: 24682747)
1. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
[TBL] [Abstract][Full Text] [Related]
2. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
[TBL] [Abstract][Full Text] [Related]
3. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G
Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505
[TBL] [Abstract][Full Text] [Related]
4. JD-02, a novel Hsp90 inhibitor, induces ROS/SRC axis-dependent cytoprotective autophagy in colorectal cancer cells.
Lan N; Su Y; Zeng Q; Zhou P; Hu Y; Zhang Z; Wang Y; Liu K
Mol Carcinog; 2024 Jun; 63(6):1038-1050. PubMed ID: 38411361
[TBL] [Abstract][Full Text] [Related]
5. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
6. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.
Karademir D; Özgür A
Med Oncol; 2023 Jul; 40(8):234. PubMed ID: 37432531
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
[TBL] [Abstract][Full Text] [Related]
8. The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer.
Eyermann CE; Haley JD; Alexandrova EM
Cell Death Dis; 2021 Jan; 12(1):126. PubMed ID: 33500390
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors.
Naz S; Banerjee T; Totsingan F; Woody K; Gross RA; Santra S
Nanotheranostics; 2021; 5(4):391-404. PubMed ID: 33912379
[No Abstract] [Full Text] [Related]
10. Novel Amidine Derivative K1586 Sensitizes Colorectal Cancer Cells to Ionizing Radiation by Inducing Chk1 Instability.
Kim HS; Park JE; Lee WH; Kwon YB; Seu YB; Kim KS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673980
[TBL] [Abstract][Full Text] [Related]
11. Gelam honey and ginger potentiate the anti cancer effect of 5-FU against HCT 116 colorectal cancer cells.
Hakim L; Alias E; Makpol S; Ngah WZ; Morad NA; Yusof YA
Asian Pac J Cancer Prev; 2014; 15(11):4651-7. PubMed ID: 24969899
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Wisniewska-Jarosinska M; Sliwinski T; Kasznicki J; Kaczmarczyk D; Krupa R; Bloch K; Drzewoski J; Chojnacki J; Blasiak J; Morawiec-Sztandera A
Mol Biol Rep; 2011 Aug; 38(6):3679-88. PubMed ID: 21107724
[TBL] [Abstract][Full Text] [Related]
13. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
[TBL] [Abstract][Full Text] [Related]
14. New ruthenium-xanthoxylin complex eliminates colorectal cancer stem cells by targeting the heat shock protein 90 chaperone.
Santos LS; Silva VR; de Castro MVL; Dias RB; Valverde LF; Rocha CAG; Soares MBP; Quadros CA; Dos Santos ER; Oliveira RMM; Carlos RM; Nogueira PCL; Bezerra DP
Cell Death Dis; 2023 Dec; 14(12):832. PubMed ID: 38102125
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.
Cardin DB; Thota R; Goff LW; Berlin JD; Jones CM; Ayers GD; Whisenant JG; Chan E
Am J Clin Oncol; 2018 Aug; 41(8):772-776. PubMed ID: 28301350
[TBL] [Abstract][Full Text] [Related]
16. Multiomic-Based Molecular Landscape of FaDu Xenograft Tumors in Mice after a Combinatorial Treatment with Radiation and an HSP90 Inhibitor Identifies Adaptation-Induced Targets of Resistance and Therapeutic Intervention.
Bylicky MA; Shankavaram U; Aryankalayil MJ; Chopra S; Naz S; Sowers AL; Choudhuri R; Calvert V; Petricoin EF; Eke I; Mitchell JB; Coleman CN
Mol Cancer Ther; 2024 Apr; 23(4):577-588. PubMed ID: 38359816
[TBL] [Abstract][Full Text] [Related]
17. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.
Bol GM; Vesuna F; Xie M; Zeng J; Aziz K; Gandhi N; Levine A; Irving A; Korz D; Tantravedi S; Heerma van Voss MR; Gabrielson K; Bordt EA; Polster BM; Cope L; van der Groep P; Kondaskar A; Rudek MA; Hosmane RS; van der Wall E; van Diest PJ; Tran PT; Raman V
EMBO Mol Med; 2015 May; 7(5):648-69. PubMed ID: 25820276
[TBL] [Abstract][Full Text] [Related]
18. Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition.
Vriend LEM; van den Tempel N; Oei AL; L'Acosta M; Pieterson FJ; Franken NAP; Kanaar R; Krawczyk PM
Oncotarget; 2017 Nov; 8(57):97490-97503. PubMed ID: 29228626
[TBL] [Abstract][Full Text] [Related]
19. Advances in DNA damage response inhibitors in colorectal cancer therapy.
Yu Y; Jia H; Zhang T; Zhang W
Acta Biochim Biophys Sin (Shanghai); 2024 Jan; 56(1):15-22. PubMed ID: 38115743
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
